The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Bioventus is one of 1024 companies in the Medical group. The Medical group currently sits ...

Core Viewpoint - Bioventus (BVS) is set to report its third-quarter 2024 earnings, with sales and earnings estimates at $132.6 million and 6 cents per share, respectively. The company has shown strong earnings surprises in recent quarters, indicating positive momentum in its financial performance [1][3]. Financial Performance - The earnings estimates for Bioventus' 2024 and 2025 EPS have remained stable at 40 cents and 45 cents, respectively, over the past 60 days [1]. - Bioventus has delivered an earnings surprise of 171.43% in the last reported quarter, with an average surprise of 102.86% over the trailing four quarters [3][4]. Revenue Growth - The company is experiencing double-digit revenue growth in its Pain Treatments and Surgical Solutions segments, with organic sales rising nearly 14% year over year in Q2 2024 [8]. - Bioventus has raised its financial guidance for 2024, expecting net sales between $557 million and $567 million, significantly higher than the original guidance of $520-$535 million [16]. Profitability and Divestitures - Management is focusing on improving profitability by divesting lower-margin businesses, including the sale of its Wound business for $85 million and the Advanced Rehabilitation business for $45 million [9][10]. - These divestitures are expected to enhance margins and cash flow, with adjusted EBITDA increasing by 22% year over year and adjusted gross margin expanding by 180 basis points to 75.8% [10]. Liquidity and Debt Management - The proceeds from divestitures are improving Bioventus' liquidity position, with a net leverage ratio reduced to less than four, and plans to lower it to below three times by the end of 2025 [11]. - Investors are likely to seek updates on the company's progress regarding liquidity and financial efficiency targets [11]. Stock Performance and Valuation - Year-to-date, Bioventus stock has surged 147.8%, outperforming the industry and the S&P 500, which saw a decline of 5.9% [13]. - The stock is currently trading at a price/sales ratio of 1.56, lower than the industry average of 2.06, indicating it is trading at a discount [15]. Investment Thesis - The company's strategic focus on accelerating growth, enhancing profitability, and improving liquidity is yielding positive results, making Bioventus a compelling addition to investment portfolios [16].

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0 ...

Shares of Bioventus (BVS) have surged 73% in the past three months, significantly outperforming the industry’s 1.3% growth. The stock has outperformed the sector and the S&P 500 during the same period. BVS' shares are also trading above the 50-day and 200-day moving averages.BVS Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThis uptick in stock price was triggered by the company’s encouraging sales performance across its business segments, especially the Pain Treatments ...

Group 1: Stock Performance - The stock price of Bioventus (BVS) has more than doubled in the past six months, significantly outperforming the industry's 5.1% rise [1] - BVS shares are trading above the 50-day and 200-day moving averages, indicating strong market performance [1] Group 2: Business Segments and Revenue Growth - Bioventus operates in three segments: Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - The company is experiencing double-digit revenue growth in both the Pain Treatments and Surgical Solutions segments, with organic sales rising nearly 14% year over year in Q2 2024 [4] Group 3: Profitability and Liquidity Improvements - Bioventus is improving profitability by focusing on higher-margin core businesses, having sold its Wound business for $85 million and planning to divest its Advanced Rehabilitation business [5] - Adjusted EBITDA increased by 22% year over year in Q2 2024, and adjusted gross margin expanded by 180 basis points to 75.8% [5] Group 4: Financial Guidance and Estimates - Management raised its financial guidance for 2024 for the second time this year, with net sales expected to be between $557 million and $567 million, up from the previous guidance of $535-$550 million [7] - Earnings per share estimates for 2024 have risen from 27 cents to 40 cents in the past 60 days, reflecting analysts' optimistic outlook [9][10] Group 5: Market Position and Investment Recommendation - Bioventus is trading at a discount to the industry, with a price/sales ratio of 1.40 compared to the industry average of 2.20 [9] - The company's focus on accelerating growth, boosting profitability, and improving liquidity is enhancing its presence in the medical products market, making it a strong candidate for investment [12][13]

Core Viewpoint - Bioventus (BVS) is a strong buy with a focus on developing drugs for quick and safe healing, particularly targeting osteoarthritis and bone healing [1] Company Overview - Bioventus, Inc. is a medical technology company specializing in proprietary orthobiologic products for musculoskeletal conditions, founded on November 23, 2011, and headquartered in Durham, NC [2] Earnings History - Bioventus has a solid earnings history, consistently beating the Zacks Consensus in the last three quarters, with an average positive earnings surprise of 102% over the last four quarters [4] Earnings Estimates Revisions - Annual earnings estimates for Bioventus are increasing, with the full year 2024 estimate rising from $0.27 to $0.40, and next year's estimate moving up from $0.43 to $0.45 over the last 30 days [5] Growth Projections - For 2024, Bioventus is expected to achieve 9.45% growth with projected sales of $560 million, increasing to $593 million in the following year for a 5.8% growth [6] Valuation Metrics - The forward PE ratio is 24x, which is considered high for the expected topline growth, while the price to book ratio is 4.1x and price to sales ratio is 1.46x, indicating potential for revenue expansion [7] - Operating margins have improved from 1% to 5.1% and up to 5.7% over the last three quarters, suggesting that growing sales and higher margins will lead to increased earnings per share [7]

Bioventus Inc. (NASDAQ:BVS) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...

Financial Performance - Q2 2024 revenue reached $151.2 million, a 10.3% increase year-over-year, with organic growth of 13.9% driven by Pain Treatments and Surgical Solutions[2] - Adjusted EBITDA from continuing operations rose by 22.4% to $34.5 million, up from $28.2 million in the prior year[2] - The company reported a net loss from continuing operations of $32.1 million, compared to a loss of $4.7 million in the prior-year period, impacted by a non-cash impairment charge of $31.9 million[2] - Net sales for the three months ended June 29, 2024, were $151,217, an increase of 10.4% compared to $137,069 for the same period in 2023[10] - Gross profit for the six months ended June 29, 2024, was $192,019, up from $163,042 for the same period in 2023, reflecting a gross margin improvement[10] - The company reported a net loss from continuing operations of $32,112 for the three months ended June 29, 2024, compared to a loss of $4,731 for the same period in 2023[10] - Adjusted EBITDA for the three months ended June 29, 2024, was $34,452 thousand, an increase from $28,158 thousand in the same period last year, reflecting a growth of approximately 22%[19] - The net loss from continuing operations for the six months ended June 29, 2024 was $(38,094), resulting in an EPS of $(0.45)[24] Guidance and Future Outlook - Bioventus raised its full-year 2024 financial guidance, now expecting net sales of $557 million to $567 million, an increase of $19.5 million from previous guidance[4] - Adjusted EBITDA guidance for 2024 is now set at $104 million to $107 million, reflecting a $9 million increase from prior guidance[4] - Non-GAAP EPS guidance for 2024 is raised to $0.36 to $0.42, an increase of $0.10 from previous estimates[4] Operational Metrics - Gross margin expanded by 350 basis points, while adjusted gross margin improved by 180 basis points compared to the prior year[1] - Cash from operations increased by 40.5% to $15.2 million in Q2 2024[1] - Total current assets increased to $308,883 as of June 29, 2024, from $267,999 as of December 31, 2023, primarily driven by higher accounts receivable[9] - Total liabilities increased to $603,111 as of June 29, 2024, compared to $589,792 as of December 31, 2023, mainly due to an increase in current liabilities[9] - Cash and cash equivalents at the end of the period were $31,994, a decrease from $36,964 at the end of 2023[11] - The Company experienced a significant increase in interest expense, totaling $9,924 thousand for the three months ended June 29, 2024, compared to $10,587 thousand in the prior year[19] Strategic Initiatives - The company received FDA clearance for the OSTEOAMP Cannula, which is expected to enhance growth opportunities in the Minimally Invasive Spine Procedure market[4] - Bioventus is pursuing the divestiture of its Advanced Rehabilitation Business to reduce debt and focus on core operations[4] - The Company deconsolidated CartiHeal effective February 27, 2023, treating it as a discontinued operation, which may impact future financial reporting[16] Research and Development - Research and development expenses for the three months ended June 29, 2024, were $3,988, compared to $3,398 for the same period in 2023, indicating a focus on innovation[10] Non-GAAP Measures - Non-GAAP Gross Profit for the six months ended June 29, 2024, was $57,075 thousand, compared to $45,109 thousand for the same period in the prior year, indicating a year-over-year increase of about 26.5%[19] - Non-GAAP net income for the six months ended June 29, 2024 was $19,944, with an adjusted EPS of $0.25[24] - The Company emphasizes the importance of Non-GAAP measures for evaluating long-term performance trends and facilitating comparisons with peers[17] - The Company does not provide U.S. GAAP financial measures on a forward-looking basis due to uncertainties related to acquisitions and other reconciling items[17] Impairment Charges - The company incurred impairment of assets amounting to $31,870 during the three months ended June 29, 2024[10] - The company incurred significant impairment charges of $31,870 in both the three and six months ended June 29, 2024, impacting overall financial performance[24]